30 completed, 1 active not recruiting, 1 terminated, 1 unknown. 33 Phase 3, 1 Phase 2.
By phase and status
Follow Hepatitis C Virus Infection: new trials by email Literature Review of Hepatitis C Virus Infection trials Research Report on Hepatitis C Virus Infection
Trials (filtered) newest first · largest first
All 33 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir - HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic Phase 3 Active not recruiting 880 2025-06-02 2026-06-29 Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection SOF/VEL, SOF/VEL/VOX - Hepatitis C Virus Infection Phase 3 Completed 87 2020-01-03 2021-10-27 Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis SOF/VEL - Hepatitis C Virus Infection Phase 3 Completed 37 2019-10-16 2022-04-20 Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 1 Hepatitis C Virus Infection Patients Seraprevir, Sofosbuvir - Hepatitis C Virus Infection Phase 3 Unknown 206 2018-10-17 2019-06-28 Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study SOF/VEL/VOX - Hepatitis C Virus Infection Phase 3 Completed 31 2017-04-25 2019-04-03 Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection SOF/VEL - Hepatitis C Virus Infection Phase 3 Completed 130 2017-03-23 2019-03-19 Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis SOF/VEL, RBV - Hepatitis C Virus Infection Phase 3 Completed 102 2016-12-26 2019-02-26 Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study Sofosbuvir, Glecaprevir/Pibrentasvir, Ribavirin - Hepatitis C Virus Infection Phase 3 Completed 33 2016-11-21 2022-05-04 Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen SOF/VEL, RBV - Hepatitis C Virus Infection Phase 3 Completed 117 2016-07-25 2018-11-14 A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2) ABT-493 coformulated with ABT-530 - Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection Phase 3 Completed 153 2016-05-17 2021-07-13 Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV SOF/VEL - Hepatitis C Virus Infection Phase 3 Completed 375 2016-04-19 2019-01-08 Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection LDV/SOF, SOF, RBV - Hepatitis C Virus Infection Phase 3 Completed 239 2016-04-12 2018-11-16 Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection SOF/VEL - Hepatitis C Virus Infection Phase 3 Completed 119 2016-04-04 2018-11-16 Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor SOF/VEL/VOX, SOF/VEL - Hepatitis C Virus Infection Phase 3 Completed 333 2015-12-23 2019-03-05 Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis SOF/VEL/VOX, SOF/VEL - Hepatitis C Virus Infection Phase 3 Completed 220 2015-12-23 2019-03-05 Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection LDV/SOF - Hepatitis C Virus Infection Phase 3 Completed 111 2015-12-22 2020-03-06 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis ABT-493/ABT-530 - Hepatitis C Virus Infection, Chronic Hepatitis C Phase 3 Completed 146 2015-12-07 2021-07-13 Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies LDV/SOF, RBV - Hepatitis C Virus Infection Phase 3 Terminated 87 2015-11-11 2018-11-16 Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection LDV/SOF, RBV - Hepatitis C Virus Infection Phase 3 Completed 255 2015-09-07 2018-11-16 Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection SOF/VEL - Hepatitis C Virus Infection Phase 3 Completed 107 2015-07-01 2018-11-16
Showing 20 of 33. Sign in to see all of them.
Narrower conditions Hepatitis C (33) · Fibrosis (7) · Hepatitis C, Chronic (7) · Liver Diseases (3) · Virus Diseases (3) · Acquired Immunodeficiency Syndrome (2) · Bronchiolitis Obliterans Syndrome (2) · Carcinoma, Hepatocellular (1) · Communicable Diseases (1) · Digestive System Diseases (1) · HIV Infections (1) · Hepatitis (1) · Hepatitis, Viral, Human (1) · Infections (1) · Liver Cirrhosis (1)
Broader conditions Blood-Borne Infections (33) · Flaviviridae Infections (33) · Communicable Diseases (32) · Digestive System Diseases (32) · Hepatitis (32) · Hepatitis, Viral, Human (32) · Infections (32) · RNA Virus Infections (32) · Liver Diseases (30) · Virus Diseases (30) · Pathologic Processes (16) · Pathological Conditions, Signs and Symptoms (16) · Disease Attributes (8) · Chronic Disease (7) · Hepatitis, Chronic (7)
Interventions sofosbuvir-velpatasvir drug combination (16) · Ribavirin (7) · Sofosbuvir (7) · ledipasvir, sofosbuvir drug combination (5) · sofosbuvir velpatasvir voxilaprevir drug combination (4) · glecaprevir and pibrentasvir (3) · Simeprevir (2) · asunaprevir (2) · daclatasvir (2) · glecaprevir (2) · pibrentasvir (2) · 8-cyclohexyl-N-((dimethylamino)sulfonyl)-1,1a,2,12b-tetrahydro-11-methoxy-1a-((3-methyl-3,8-diazabicyclo(3.2.1)oct-8-yl)carbonyl)cycloprop(d)indolo(2,1-a)(2)benzazepine-5-carboxamide (1) · Introns (1) · dasabuvir (1) · ombitasvir (1)
Sponsors Gilead Sciences (21) · AbbVie (4) · Bristol-Myers Squibb (2) · Janssen Infectious Diseases BVBA (2) · Atea Pharmaceuticals, Inc. (1) · Ginkgopharma CO., LTD (1) · National Cancer Institute, Milan (1) · Ullevaal University Hospital (1)
Countries United States (13) · Canada (10) · Germany (8) · Puerto Rico (8) · France (7) · United Kingdom (7) · Japan (6) · Australia (5) · New Zealand (5) · China (4) · Italy (4) · Russia (3) · South Korea (3) · Belgium (2) · Egypt (2)
Top investigators John McNally, PhD (2) · Anu M Osinusi, MD, MPH (1) · Anu Osinusi, MD (1) · Olav Dalgard, MD PhD (1) · Rolando Viani, MD (1) · Vincenzo Mazzaferro, MD (1) · Xuegang Wu (1)
Results publications PMID 27847279 , PMID 36740893 , PMID 26575258 , PMID 30529905 , PMID 30977945 , PMID 17133492 , PMID 26569658 , PMID 26571066 , PMID 26743093 , PMID 26799692 , PMID 27919899 , PMID 28369210 , PMID 28390869 , PMID 28404069 , PMID 28412293 , PMID 28564569 , PMID 29091342 , PMID 29174546 , PMID 29177645 , PMID 29666174 , PMID 30012435 , PMID 30499360 , PMID 30555048 , PMID 30868245 , PMID 30923816 , PMID 31216086 , PMID 31568620 , PMID 34864948 , PMID 35802063
NIH funding 2015 (6) , 2014 (3) , 2016 (1) , 2017 (1)